McPhy Energy : Procédure de redressement judiciaire et offres de reprise - Point de situation Foussemagne (France), le 25 juin 2025 – 17h45 CEST McPhy Energy (« McPhy ») annonce que, lors d’une audience en date du 24 juin 2025, le Tribunal de commerce de Belfort (le « Tribunal ») a examiné les offres de reprise déposées dans le cadre de la procédure de redressement judiciaire1. Le délibéré a été fixé au 8 juillet 2025. Qu’une offre de reprise soit adoptée ou non par le Tribunal, il est anticipé que le redressement judiciaire ouvert à l’égard de McPhy sera converti en liquidation judici...
McPhy Energy: Judicial reorganization and offers - Update Foussemagne (France), June 25, 2025 – 5.45 p.m. CEST McPhy Energy (“McPhy”) announces that, during the hearing on June 24, 2025, the Belfort Commercial Court (the “Court”) reviewed the offers submitted as part of the judicial reorganization process1. The deliberation has been set for July 8, 2025. Whether or not an offer is adopted by the Court, it is anticipated that the judicial reorganization opened against McPhy will be converted into judicial liquidation to allow the liquidation of the assets and activities not transferred. ...
The market environment remains fragile but small caps are showing encouraging signs, staging indeed a return to their old outperformance YTD in 2025. We expect this asset class to maintain the rebound initiated a few months ago, thanks to : 1/ discounted valuations, 2/ a growth premium, and 3/ the potential for a return of flows. After an outperformance of 9% in H1 (+2.8 points in vs MSCI small cap Europe), we are adjusting our H2 2025 Nextcap conviction list, which now includes : CM.com, Compag...
Le contexte de marché demeure encore fragile, mais les signaux sont encourageants sur les small caps qui affichent un retour à une surperformance YTD 2025. Nous pensons que cette classe d’actifs devrait continuer son rebond initié depuis quelques mois grâce à : 1/ des valorisations toujours décotées, 2/ une certaine prime de croissance et 3/ un potentiel retour des flux. Après une surperformance de 9% (+2.8 points vs MSCI small cap Europe) au S1, nous ajustons notre liste de convictions Nextcap ...
MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.